KITLG and neoplasm: Similarly, Wu et al. screened and identified a small molecule inhibitor specific for SCF-SKP2 activity, which selectively inhibits SKP2-mediated p27 degradation in cancer cells by reducing p27 binding via key compound-receptor contacts, thereby inhibiting tumor growth 63.